What's Hot
View all perspectives
Rheum Cat rheum_cat
4 years ago
Talk on collaborative research and team building by @rheum_covid leaders @JYazdanyMD & @philipcrobinson
Dr. Yazdany with an illustration of what the journey might look like for the ECI phase & beyond
#ACR20 #ACRambassador https://t.co/ISNQSrFWws
Dr Irwin Lim _connectedcare
4 years ago
SELECT-PsA2 group refractory to prior bDMARD therapy
UPA - useful oral JAKi option in Psoriatic Arthritis
Safety consistent with what we know from RA. More Sfx at 30mg. No clear VTE signal
#ACR20 https://t.co/XpprRprugI
Dr Philip Robinson philipcrobinson
4 years ago
Cohort study of 186 AI patients from New York => Among patients hospitalized with COVID-19, individuals with autoimmune disease did not have an increased risk of a composite outcome of intensive care unit admission, intubation, or death.
https://t.co/EXGyfrHnjH @jrheum
Peter Nash drpnash
4 years ago
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies https://t.co/itrgSeNted #RA #prednisone 18-30% flare ceasing Pred - imi for bridging rather than commence oral! Eular guidelines have a lot to answer for
Peter Nash drpnash
4 years ago
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years https://t.co/9YNEGXKoAD #RA #filgotinib low vte & low zoster rates
Peter Nash drpnash
4 years ago
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis https://t.co/T3cXYlCSRC #RA #Upadacitinib 3 yr safety data
Peter Nash drpnash
4 years ago
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms https://t.co/sLGxMwJUhk #SLE #fatigue - fatigue remains a big problem
Dr Ai Lyn Tan DrAiLynTan
4 years ago
Tender non-swollen joints NOT associated with #ultrasound synovitis in DMARD-naïve early #PsoriaticArthritis
👉🏽https://t.co/XcuhlZbpSV
by Dr Dubash @LeedsTeamSpA @LeedsBRC
#ACR20 #0313 https://t.co/TbpxIy83Qt
Outcomes for Rheumatic Disease Patients with COVID-19: Dr Kathryn Dao
Dr. Kathryn Dao discusses plenary abstract #0430 presented Friday at the ACR 2020 annual meeting.
Peter Nash drpnash
4 years ago
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report https://t.co/zdpk6IvxP0 #PsA # predictors
Peter Nash drpnash
4 years ago
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
Mrinalini Dey DrMiniDey
4 years ago
Was delighted to speak to Dr Marwan Bukhari @drdj, Editor-in-Chief of Rheumatology, yesterday at #ACR20. We discussed journal activities over the past year & his personal congress highlights. Watch the video below!
Follow the journal👉@RheumJnl
@RheumNow
https://t.co/C7WW4Ep1Sk
Treat to Target for PsA Patients Abstracts: Dr. Rachel Tate
Dr. Tate discusses abstracts #0321, #0324, #0320 and #0344 presented at the ACR20 annual meeting.
Dr. Janet Pope interviews A&R Editor Dr. Daniel Solomon
Dr. Janet Pope interviews Arthritis & Rheumatology Editor Dr. Daniel Solomon about his role as editor, COVID-19 related submissions, and overall journal submissions
Advanced Imaging for Crystal Arthritis: Which Test is Best? Dr. Nicola Dalbeth
Dr. Nicola Dalbeth of Aukland, New Zealand examines abstracts #0647 and #1542 involving imaging studies for crystal arthritis at ACR 2020.
Poster Hall